Herantis Pharma announces publication of preclinical HER-096 data in Cell Chemical Biology journal

Herantis Pharma Plc | Press Release | December 01, 2023 at 09:00:00 EET

Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease, today announced a publication in Cell Chemical Biology journal.

Title of the publication: HER-096 is a CDNF-derived brain-penetrating peptidomimetic that protects dopaminergic neurons in a mouse synucleinopathy model of Parkinson’s disease.

The publication summarizes preclinical development data on subcutaneously administered HER-096, including pharmacokinetics and distribution data in rats and mice, and demonstration of therapeutic effects in an aged mouse model of Parkinson’s disease.

The open access article can be accessed via this link:


“This publication demonstrates blood-brain barrier penetration in animals and therapeutic potential of HER-096 in a highly relevant animal model of neurodegeneration“, said Henri Huttunen, CSO of Herantis Pharma and the senior author of the publication. “Thanks to our network of highly capable drug development experts, both internally and externally, we have been able to advance HER-096 rapidly since the preclinical candidate selection in May 2021.”

On October 25th, 2023, Herantis Pharma announced positive topline data from the Phase 1a clinical trial of HER-096 tested in healthy volunteer subjects:

  • HER-096 Phase 1a clinical trial met primary and secondary endpoints;
  • Subcutaneous single dose injections of HER-096 had overall good safety and tolerability profile in young and older healthy subjects;
  • The pharmacokinetic profile showed fast uptake of HER-096 after subcutaneous injection and demonstrated blood-brain barrier (BBB) penetration in humans.

About Cell Chemical Biology:

Cell Chemical Biology (https://www.cell.com/cell-chemical-biology/home) is a peer-reviewed scientific journal published by Cell Press. The journal publishes research in chemical biology and studies at the interface of chemistry and biology.

For more information, please contact:
Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. A Phase 1a clinical trial has demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com